Changing the standard of care for stage III melanoma surgery

Source: Science Daily, March 2022

Date: March 4, 2022

Source: University of Colorado Anschutz Medical Campus

Summary: For years, surgery for patients with stage III melanoma — melanoma that has spread to the lymph nodes — involved removing those lymph nodes along with the primary tumor. Known as completion lymph node dissection (CLND), the surgery was meant to ensure that no cancer remained after surgery. More recently, however, cancer surgeons have discovered that CLND has the potential to cause more problems than it solves. In most cases, patients do better on immunotherapy alone than they do when their surgery involves removal of the lymph nodes, due to potential complications from lymph node surgery.

READ THE ORIGINAL FULL ARTICLE
Menu